PLUR Earnings Date: Nov 5, 2026 (Estimated) — Pluri Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PLUR's next earnings date?
Pluri Inc. (PLUR) is expected to report Q1 2027 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company.
How did PLUR do in its last earnings report?
In its most recent report on Sep 10, 2026 (Q4 2026), Pluri Inc. posted EPS of -$0.54 versus the -$0.66 estimate, a beat of 18.2%. Revenue was $335,000 against a $655,000 estimate. The stock's 1-day post-earnings move was -5.6%.
How much does PLUR stock move after earnings?
PLUR beat EPS estimates in 3 of its last 5 reported quarters. Over the last 8 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Pluri Inc.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | Q4 2026 | -0.66 | -0.54 | +18.18% | $335,000 | ✅ Beat | -5.60% | -13.60% | -23.74% |
| 2026-05-14 | Q3 2026 | -0.66 | -0.55 | +16.67% | $167,000 | ✅ Beat | -0.88% | -32.35% | -31.47% |
| 2026-02-12 | Q2 2026 | -0.65 | -0.71 | -9.23% | $198,000 | ❌ Miss | +0.28% | +3.10% | -7.44% |
| 2025-11-12 | Q1 2026 | -0.74 | -0.65 | +12.16% | $316,000 | ✅ Beat | -6.07% | -19.89% | -30.79% |
| 2025-09-17 | Q4 2025 | -0.73 | -1.00 | -36.99% | $398,000 | ❌ Miss | -4.21% | -5.00% | -7.45% |
| 2025-02-11 | Q2 2025 | — | -0.53 | — | $185,000 | — | +0.89% | +4.12% | +7.81% |
| 2024-09-18 | Q4 2024 | — | -1.07 | — | $96,000 | — | +5.19% | +13.96% | -7.44% |
| 2024-05-10 | Q3 2024 | — | -1.01 | — | $71,000 | — | +6.96% | +4.90% | -3.35% |
Showing last 8 quarters.